Novo Nordisk (NVO) total debt
Novo Nordisk (NVO) carried total debt of DKK 130.96B at the end of fiscal 2025 (December 31, 2025). That is 27.4% higher than the DKK 102.79B of fiscal 2024. Figures as of 18 Nov 2026, 08:18 UTC, from Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- DKK 130.96B
- Change on fiscal 2024
- +27.4%
- Highest on record
- DKK 130.96Bfiscal 2025
- Lowest on record
- DKK 25.78Bfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in DKK. Figures, not advice.
Novo Nordisk total debt, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was DKK 130.96B in fiscal 2025 and the lowest DKK 25.78B in fiscal 2022.
Total debt was 0.7× shareholders' equity at the end of fiscal 2025.
Total debt by fiscal year
Novo Nordisk total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | DKK 130.96B | 27.4% up | 0.7× | |
| 2024 | DKK 102.79B | 280.6% up | 0.7× | |
| 2023 | DKK 27.01B | 4.7% up | 0.3× | |
| 2022 | DKK 25.78B | — | 0.3× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Total debt at health care companies of similar size
| Company | Total debt | Fiscal year |
|---|---|---|
| Gilead Sciences GILD | $24.94B | 2025 |
| Abbott Laboratories ABT | $13.86B | 2025 |
| Novo Nordisk NVO | DKK 130.96B | 2025 |
| Pfizer PFE | $63.96B | 2025 |
| Danaher DHR | $19.70B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Novo Nordisk, figure by figure
- Novo Nordisk market cap
- Novo Nordisk revenue
- Novo Nordisk earnings
- Novo Nordisk earnings per share (EPS)
- Novo Nordisk P/E ratio
- Novo Nordisk P/S ratio
- Novo Nordisk P/B ratio
- Novo Nordisk free cash flow
- Novo Nordisk operating margin
- Novo Nordisk dividend
- Novo Nordisk shares outstanding
- Novo Nordisk cash on hand
- Novo Nordisk total assets
- Novo Nordisk return on equity (ROE)
- Novo Nordisk return on invested capital (ROIC)
Novo Nordisk (NVO) overview: price, valuation and scorecardAll health care companies by market value
Novo Nordisk total debt: questions and answers
How much debt does Novo Nordisk have?
Novo Nordisk (NVO) carried total debt of DKK 130.96B at the end of fiscal 2025 (December 31, 2025). That is 27.4% higher than the DKK 102.79B of fiscal 2024.
What are the highest and lowest total debt figures on record for Novo Nordisk?
Across the 4 fiscal years on record (2022–2025), the highest was DKK 130.96B in fiscal 2025 and the lowest DKK 25.78B in fiscal 2022.
How does Novo Nordisk's debt compare with its equity?
Total debt was 0.7× shareholders' equity at the end of fiscal 2025.
How is Novo Nordisk's total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Novo Nordisk (NVO) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/NVO/total-debt
Underlying data: Yahoo Finance.